ArticleScientific reports2024
Value creation of copra meal mannan into functional manno-oligosaccharides (β-MOS) using the mannanase Bacillus man B (BlMan26B).
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Production of Xylooligosaccharides (XOSs) with Anti-inflammatory and Prebiotic Activities Using Recombinant Endo-1,4-β-xylanases fromJournal of agricultural and food chemistry · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
Agricultural wastes rich in β-mannan are an important environmental problem in tropical and sub-tropical countries. This research aims at dealing with this and investigates the valorization of mannan-rich copra meal from virgin coconut oil manufacturing into mannan-oligosaccharides (β-MOS) by enzymatic hydrolysis using β-mannanase from Bacillus licheniformis (BlMan26B). Lab-scale process, involving pre-treatment and bioconversion steps, were conducted and evaluated. Lyophilized β-MOS was analyzed and its biological activities were assessed. The size of oligosaccharides obtained ranged from dimers to hexamers with 36.7% conversion yields. The prebiotic effects of β-MOS were demonstrated in comparison with commercial inulin and fructo-oligosaccharides (FOS). In vitro toxicity assays of β -MOS on human dermal fibroblasts and monocytes showed no cytotoxic effect. Interestingly, β-MOS at concentrations ranging from 10 to 200 µg/mL also demonstrated potent anti-inflammatory activity against LPS-induced inflammation of human macrophage THP-1 in a dose-dependent manner. However, at high dose, β-MOS could also stimulate inflammation. Therefore, further investigation must be conducted to ensure its efficacy and safe use in the future. These results indicate that β-MOS have the potential to be used as valued-added health-promoting nutraceutical or feed additive after additional in-depth studies. These finding should be applicable for other agricultural wastes rich in mannan as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.